Management peculiarities of patients with chronic tonsillitis in comorbid conditions

Abstract

Introduction. Chronic tonsillitis (CT) remains an urgent challenge in outpatient practice of not only otorhinolaryngologists, but also multi-discipline specialists – primary care physicians and general practitioners.Aim. To study the effectiveness of Tonsilgon® N at the outpatient care stage in CT patients with and without comorbidities. Materials and methods. 62 patients (30 to 56 years of age, average age 43.8 ± 13.2 years) with compensated CT were treated. The patients were divided into two groups: Group 1 (n = 30) included patients with compensated CT, Group 2 (n = 32) – patients with compensated CT and comorbidities: diabetes mellitus was detected in 40.6%, autoimmune thyroiditis in 43.7%, psoriasis in 15.7% of examined patients.Results and discussion. Evaluation of treatment outcomes using a 10-point visual analogue scale showed a significant (p < 0.05) health improvement in patients of both groups who received Tonsilgon® N. The examination showed a 1.8-fold decrease in the severity of the local symptom of CT – hyperemia and a roll-like thickening of the edges of the pillars of the fauces in patients of both groups by the 7th day of treatment. The trends of changes were characterized by uniformity, amounting to 0.09 ± 0.02 scores in Group 1 and 0.1 ± 0.02 scores in Group 2 (p < 0.05) by the 14th day of treatment. In CT patients without comorbidities, exacerbations that developed within 3 months were only observed in 6.6% of patients, and occurred in a mild form, which made it possible to abandon the use of antibacterials for systemic use; in Group 2 with comorbidities, they were more common and developed in 12.5% of patients.Conclusion. The high rate of successful treatment outcomes confirms the safety of the drug as an effective agent to relieve the severity of CT symptoms.